COLL

+ Watchlist + Portfolio

Collegium Pharmaceutical, Inc.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $28.74
52-Week Range: $25.47 – $50.79
Market Cap: $853.72M
P/E (TTM): 21.69
EPS (TTM): 1.27
Dividend Yield: —

Advanced Metrics

Price/Book: 2.87
PEG Ratio: —
Return on Equity: 17.61%
Return on Assets: 5.76%
Gross Margin: 89.45%
Operating Margin: 5.65%
Profit Margin: 5.93%
Current Ratio: 1.03
Debt/Equity: 3.90
Total Debt: $1.22B
Free Cash Flow: $324.04M
Revenue Growth: 6.30%
Earnings Growth: —
Enterprise Value: $2.02B

COLL Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$463.93M	$566.77M	$631.45M	$780.57M
Cost of Revenue	$254.44M	$240.60M	$254.10M	$317.31M
Gross Profit	$209.49M	$326.17M	$377.34M	$463.26M
Research & Development	$3.98M	$0.00	$0.00	—
Selling, General & Admin	$172.19M	$159.21M	$210.36M	$284.80M
Operating Expenses	$176.17M	$159.21M	$210.36M	$284.80M
Operating Income	$33.32M	$166.96M	$166.98M	$178.45M
EBITDA	$173.31M	$308.33M	$341.70M	$401.00M
Pretax Income	-$28.85M	$75.73M	$98.57M	$92.62M
Income Tax	-$3.85M	$27.58M	$29.38M	$29.75M
Net Income	-$25.00M	$48.16M	$69.19M	$62.87M
Diluted EPS	-0.74	1.29	1.86	1.73
Diluted Shares	33.83M	41.79M	40.42M	39.70M

COLL Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$173.69M	$238.95M	$70.56M	$231.25M
Receivables	$183.12M	$179.53M	$228.54M	$211.33M
Inventory	$46.50M	$32.33M	$35.56M	$40.91M
Current Assets	$419.99M	$537.60M	$482.26M	$691.41M
Total Assets	$1.17B	$1.14B	$1.66B	$1.66B
Current Liabilities	$433.73M	$457.92M	$509.51M	$440.03M
Long-Term Debt	$538.45M	$483.84M	$787.90M	$780.33M
Total Debt	$709.17M	$674.28M	$859.30M	$814.86M
Total Liabilities	$979.29M	$947.88M	$1.43B	$1.36B
Retained Earnings	-$281.34M	-$233.19M	-$164.00M	-$101.13M
Shareholders' Equity	$194.84M	$195.43M	$228.84M	$301.68M
Working Capital	-$13.74M	$79.69M	-$27.25M	$251.38M
Net Debt	$527.26M	$428.22M	$781.92M	$578.07M

COLL Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	$124.23M	$274.75M	$204.98M	$329.32M
Capital Expenditure	-$1.62M	-$461.00K	-$1.65M	-$1.74M
Free Cash Flow	$122.61M	$274.29M	$203.33M	$327.58M
Depreciation & Amortisation	$138.94M	$149.26M	$169.16M	$226.07M
Stock-Based Compensation	$22.87M	$27.14M	$32.40M	$41.91M
Investing Cash Flow	-$573.69M	-$70.81M	-$287.76M	-$63.53M
Financing Cash Flow	$436.72M	-$140.18M	-$60.60M	-$110.25M
Share Repurchases	-$14.06M	-$75.00M	-$60.02M	-$25.10M
Net Change in Cash	-$12.74M	$63.76M	-$143.38M	$155.55M

COLL Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Revenue	$177.76M	$188.00M	$209.36M	$205.45M	$193.52M
Cost of Revenue	$80.43M	$79.62M	$80.19M	$77.07M	$76.27M
Gross Profit	$97.32M	$108.38M	$129.17M	$128.38M	$117.25M
Selling, General & Admin	$76.42M	$73.64M	$67.10M	$67.64M	$86.35M
Operating Expenses	$76.42M	$73.64M	$67.10M	$67.64M	$86.35M
Operating Income	$20.90M	$34.75M	$62.07M	$60.74M	$30.90M
EBITDA	$80.48M	$94.10M	$121.71M	$104.72M	$90.54M
Pretax Income	$3.12M	$17.02M	$43.44M	$29.04M	$18.74M
Income Tax	$705.00K	$5.04M	$11.93M	$12.07M	$4.24M
Net Income	$2.42M	$11.98M	$31.51M	$16.96M	$14.50M
Diluted EPS	0.07	0.34	0.84	0.46	0.40
Diluted Shares	32.84M	39.08M	39.44M	40.08M	40.07M

COLL Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Cash & Equivalents	$96.19M	$117.35M	$150.10M	$231.25M	$268.65M
Receivables	$228.71M	$213.02M	$233.95M	$211.33M	$228.76M
Inventory	$37.22M	$38.15M	$38.05M	$40.91M	$42.74M
Current Assets	$527.55M	$549.21M	$613.87M	$691.41M	$745.67M
Total Assets	$1.63B	$1.59B	$1.61B	$1.66B	$1.65B
Current Liabilities	$486.71M	$464.61M	$452.93M	$440.03M	$434.97M
Long-Term Debt	$773.13M	$758.34M	$743.53M	$780.33M	$770.20M
Total Debt	$844.21M	$829.11M	$813.99M	$814.86M	$808.06M
Total Liabilities	$1.40B	$1.36B	$1.33B	$1.36B	$1.34B
Retained Earnings	-$161.58M	-$149.60M	-$118.09M	-$101.13M	-$86.63M
Shareholders' Equity	$234.43M	$232.21M	$274.81M	$301.68M	$312.42M
Working Capital	$40.84M	$84.60M	$160.94M	$251.38M	$310.69M
Net Debt	$741.52M	$705.57M	$658.02M	$578.07M	$534.17M

COLL Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Operating Cash Flow	$55.40M	$72.44M	$78.44M	$123.05M	$57.11M
Capital Expenditure	-$798.00K	-$65.00K	-$188.00K	-$689.00K	-$270.00K
Free Cash Flow	$54.60M	$72.37M	$78.25M	$122.36M	$56.84M
Depreciation & Amortisation	$56.56M	$56.61M	$56.51M	$56.40M	$55.94M
Stock-Based Compensation	$11.52M	$10.82M	$9.81M	$9.75M	$10.88M
Investing Cash Flow	-$9.68M	-$2.92M	-$30.87M	-$20.07M	$1.63M
Financing Cash Flow	-$25.24M	-$48.37M	-$14.82M	-$21.82M	-$21.34M
Share Repurchases	—	—	$0.00	$0.00	—
Net Change in Cash	$20.48M	$21.15M	$32.75M	$81.16M	$37.40M

Market Snapshot

About

Collegium Pharmaceutical, Inc. is a specialty pharmaceutical company focused on developing and commercializing medicines for pain management. Headquartered in Stoughton, Massachusetts, the company's flagship product is Xtampza ER, an abuse-deterrent extended-release oxycodone formulation. Collegium utilizes proprietary DETERx technology platform to create formulations designed to deter abuse while maintaining therapeutic efficacy. The company markets its products to healthcare professionals treating patients with pain conditions requiring around-the-clock opioid treatment.